Hepatic Encephalopathy Market to Witness Robust Growth, Reaching $2.1 Billion by 2028 As Per The Business Research Company's Hepatic Encephalopathy Global Market Report 2024
March 06, 2024 11:30 ET
|
TBRC Business Research PVT LTD
LONDON, March 06, 2024 (GLOBE NEWSWIRE) -- As per The Business Research Company’s Hepatic Encephalopathy Global Market Report 2024, the global hepatic encephalopathy market, a condition arising from...
GENFIT annonce son chiffre d’affaires et sa position de trésorerie au 31 décembre 2023
February 29, 2024 16:10 ET
|
GENFIT S.A.
Trésorerie et équivalents de trésorerie : 77,8 millions d’euros au 31 décembre 2023 Chiffre d’affaires : 28,6 millions d’euros au 31 décembre 2023, dont un paiement d’étape de 13,3 millions d’euros...
GENFIT Announces Revenues and Cash Position as of December 31, 2023
February 29, 2024 16:10 ET
|
GENFIT S.A.
Cash and cash equivalents totaled €77.8 million as of December 31, 2023Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 million Upcoming FDA PDUFA...
Ascites Market to Observe Stunning Growth During the Study Period (2019–2032) | DelveInsight
February 21, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ascites Market to Observe Stunning Growth During the Study Period (2019–2032) | DelveInsight The rise in the patient population of ascites, the...
Primary Biliary Cholangitis Pipeline: Insight 2023 Report Highlights Emerging Therapies and Key Players
January 24, 2024 10:51 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Primary Biliary Cholangitis - Pipeline Insight, 2023" report has been added to ResearchAndMarkets.com's offering. A comprehensive analysis entitled...
GENFIT annonce son calendrier financier pour 2024
January 15, 2024 16:10 ET
|
GENFIT S.A.
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 15 janvier 2024 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique de stade clinique avancé engagée dans...
GENFIT Announces 2024 Financial Calendar
January 15, 2024 16:10 ET
|
GENFIT S.A.
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
January 11, 2024 16:10 ET
|
GENFIT S.A.
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 11 janvier 2024 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique de stade clinique avancé engagée dans...
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
January 11, 2024 16:10 ET
|
GENFIT S.A.
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 11, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)
December 08, 2023 01:55 ET
|
GENFIT S.A.
US Food and Drug Administration (FDA) has granted Priority Review for New Drug Application (NDA) for elafibranor in PBC, and European Medicine Agency (EMA) has also validated the Marketing...